Develops peripheral quantitative computed tomography (pQCT) bone and muscle measurement systems. Markets and services pQCT systems for research and clinical applications. Now — the numbers.
This is an established company with proven profits.
An average decline of 5% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
The gap is $338K. In times of high interest rates, a gap like that can squeeze a company.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
The net profit margin is 27% — that slice of every sale is the company’s cushion in hard quarters.
The stock sits at $0.0001. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
Over the last 8 years, sales fell about 5% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.